Skip to main content

Table 2 Clinical parameters and biomarker levels of axSpA at baseline and after 6 months of exercise therapy

From: Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

 

All axSpA

nr-axSpA

AS

(n = 40)

(n = 18)

(n = 22)

Baseline

6 months

P value

Baseline

6 months

P value

Baseline

6 months

P value

ASDAS-CRP

2.10 ± 0.12

1.84 ± 0.11

<0.01

2.01 ± 0.19

1.73 ± 0.16

<0.05

2.17 ± 0.16

1.93 ± 0.15

ns

BASDAI

2.78 ± 0.31

2.30 ± 0.25

ns

2.98 ± 0.28

2.27 ± 0.41

ns

2.63 ± 0.35

2.31 ± 0.32

ns

BASFI

1.06 ± 0.16

1.01 ± 0.14

ns

1.23 ± 0.28

1.73 ± 0.16

ns

0.92 ± 0.17

0.93 ± 0.18

ns

BASMI

1.28 ± 0.14

0.66 ± 0.84

<0.0001

1.09 ± 0.12

0.47 ± 0.08

<0.0001

1.43 ± 0.24

0.82 ± 0.23

<0.0001

CRP (mg/l)

4.67 ± 0.89

3.86 ± 0.82

ns

2.10 ± 0.48

2.16 ± 0.56

ns

6.76 ± 1.45

5.24 ± 1.37

ns

IL-6 (pg/ml)

10.31 ± 3.93

10.07 ± 4.60

ns

14.78 ± 8.35

15.40 ± 9.79

ns

6.48 ± 1.46

5.51 ± 1.63

ns

IL-17 (pg/ml)

323.50 ± 57.06

401.50 ± 75.87

ns

349.20 ± 82.55

285.30 ± 72.73

ns

301.80 ± 80.57

499.30 ± 123.10

ns

TNF-α (pg/ml)

65.22 ± 12.30

56.89 ± 10.61

ns

55.87 ± 10.49

45.03 ± 6.76

ns

72.49 ± 20.45

62.12 ± 18.06

ns

Calprotectin (ng/ml)

2408.0 ± 183.30

1800.0 ± 101.90

<0.001

2379.0 ± 243.20

1779.0 ± 138.30

<0.01

2430.0 ± 269.70

1816.0 ± 148.20

<0.01

  1. The statistical significance was determined as a p value < 0.05; the paired non parametric test (Wilcoxon) was used for analysis of baseline versus 6 month data for each group. All data are characterised as mean ± standard deviation. axSpA axial spondyloarthritis, nr-axSpA non-radiographic axial spondyloarthritis, AS ankylosing spondylitis, ASDAS-CRP AS disease activity score, CRP C-reactive protein, BASDAI Bath AS disease activity index, BASFI Bath AS functional index, BASMI Bath AS metrology index, IL interleukin, TNF tumour necrosis factor, ns not significant
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us